Related Experiment Video
Updated: May 24, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Antiplatelet therapy in acute myocardial infarction complicated by cardiogenic shock
Angela Dettling1,2,3, Kurt Huber4, Steen D Kristensen5
1Department of Cardiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. a.dettling@uke.de.
Insights
Managing blood clots is crucial for patients with cardiogenic shock (CS) after heart attack. Balancing effective antithrombotic therapy to prevent clots while minimizing bleeding risk is key for improving survival in these high-risk individuals.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) carries a high mortality rate, approximately 50%.
- Effective antithrombotic therapy is critical for improving outcomes in acute coronary syndromes, especially in high-risk CS patients.
- CS patients face a dual risk of thrombotic and bleeding complications, complicating therapeutic decisions.
Purpose of the Study:
- To review current practices and challenges in antithrombotic therapy for AMI with CS.
- To evaluate the safety, efficacy, and outcomes of antiplatelet and antithrombotic agents in this population.
- To discuss the role of parenteral platelet inhibitors in managing CS.
Main Methods:
- Literature review of existing evidence on antithrombotic therapy in CS.
- Analysis of factors influencing drug efficacy and safety, including drug administration, metabolism, and mechanical circulatory support (MCS).
- Focus on adjunctive antiplatelet and antithrombotic strategies.
Main Results:
- Balancing antithrombotic therapy in CS is challenging due to high risks of both thrombosis and bleeding.
- Mechanical circulatory support (MCS) introduces further complexities in managing antithrombotic regimens.
- Parenteral platelet inhibitors are discussed as a potential therapeutic option.
Conclusions:
- Optimizing antithrombotic therapy in AMI with CS requires careful consideration of individual patient risk factors.
- Further research is needed to establish optimal strategies for balancing efficacy and safety.
- Individualized approaches to antithrombotic management are essential for improving survival in CS patients.
Abstract:
Coronary revascularization represents a cornerstone in the treatment of infarct-related cardiogenic shock (CS). Early and effective antithrombotic therapy is critical and has been shown to improve mortality in most patients with acute coronary syndrome. Achieving early effective platelet inhibition and anticoagulation, with minimal risk, is particularly important in those high-risk patients with CS as the mortality remains high at approximately 50%. However, patients with CS are at high risk for both early thrombotic as well as bleeding events and striking the right balance remains a challenge due to a multitude of factors related to drug administration, metabolism and mechanical issues related to therapeutic interventions such as increasing use of mechanical circulatory support (MCS). This review therefore aims to provide an overview of the current practice, the underlying challenges and existing evidence on safety, efficacy and outcomes of adjunctive antiplatelet and antithrombotic therapy in patients with acute myocardial infarction (AMI) complicated by CS and discusses the use of parenteral platelet inhibitors.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:24Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...